Deletion of the INK4a/ARF locus at 9p21 is detected with high frequency in human melanoma. Within a short genomic distance, this locus encodes several proteins with established tumor-suppressor roles in a broad spectrum of cancer types. Several lines of evidence support the view that p16
Deletion of the INK4a/ARF locus at 9p21 is detected with high frequency in human melanoma. Within a short genomic distance, this locus encodes several proteins with established tumor-suppressor roles in a broad spectrum of cancer types. Several lines of evidence support the view that p16
INK4a and p19 ARF exert the tumor-suppressor activities of this locus, although their relative importance in specific cancer types such as melanoma has been less rigorously documented on the genetic level. Here, we exploit a well-defined mouse model of RAS-induced melanomas to examine the impact of germline p16 INK4a or p19 ARF nullizygosity on melanoma formation. We demonstrate that loss of either Ink4a/Arf product can cooperate with RAS activation to produce clinically indistinguishable melanomas. In line with the common phenotypic end point, we further show that RAS þ p16 (Flores et al., 1996; Walker et al., 1998) which, along with B-RAF mutations (Davies et al., 2002) (Schmid et al., 1998) 
or p15
INK4b (Glendening et al., 1995) .
Previous work in the mouse has demonstrated that activated H-RAS expression can potently synergize with the combined loss of p16
INK4a and p19 ARF in the formation of murine melanoma (Chin et al., 1997) . The presence of H-or N-RAS-activated alleles, coupled with the reciprocal presence of B-RAF mutations, has underscored the central role of the RAS/RAF pathway in melanoma (Herlyn and Satyamoorthy, 1996; Davies et al., 2002) and further suggests that RAS-driven transgenic mice (Tyr-RAS) provide a relevant model to understand the genetic principals governing human melanoma pathogenesis. Along these lines, it is worth mentioning that RAS-induced melanoma on an Ink4a/ ArfÀ/À background harbored secondary genomic alterations in regions syntenic to known gains/losses in human melanoma (L Chin, unpublished observation), further validating the use of this model for elucidation of melanoma genetics. Given the described synergy of Ink4a/Arf loss and RAS expression in melanoma formation, we used p16
INK4a and p19 ARF specific KO strains as a system to address the roles of each protein in suppressing RAS-induced melanoma formation in vivo. This is the first in vivo comparison of these targeted alleles engineered with similar targeting strategies (deletion of the first exon with excision of the selectable marker), and performed concurrently in a single facility.
Here, to dissect the relative contributions of the two Ink4a/Arf gene products, Tyr-RAS mice were examined in the setting of specific deficiencies for p16 Table 1 ). Tyr-RAS transgenic animals on either KO background succumbed to melanomas with significantly shortened tumor latency compared to Tyr-RAS littermate controls with intact Ink4a/Arf function (Figure 1a ), although mice with loss of Ink4a/Arf function (i.e., the allele that eliminates both p16
INK4a and p19 ARF ) remained most susceptible. Specifically, Tyr-RAS Ink4a/ArfÀ/À mice show a median melanoma-free survival of 24 weeks (Chin et al., 1997) compared with 75 and 40 weeks for Tyr-RAS animals on p16
INK4a À/À or p19 ARF À/À backgrounds, respectively ( Figure 1a ). In contrast, none of the Tyr-RAS littermates in either p16
INK4a þ / þ or p19 ARF þ / þ control cohorts developed melanoma by 89 weeks of age. These findings provide unequivocal genetic proof of a role of both products of the Ink4a/Arf locus in melanoma suppression.
Melanocytic tumors from either KO strain were TRP1 positive and appeared histologically and clinically similar to those described previously in Tyr-RAS Ink4a/ ArfÀ/À mice ( Figure 1b) (Chin et al., 1997) . Although there was a tendency for melanomas from p16
INK4a À/À animals to exhibit a more spindle and less epithelioid morphology (Figure 1b) , such histopathological features were not consistently or specifically associated withp16
INK4a deficiency. In other words, the histopathological appearances of these RAS-induced tumors from all the three genetic backgrounds (p16 
INK4a þ /À (n ¼ 24) and Tyr-RAS þ p16 INK4a À/À (n ¼ 17) were observed for spontaneous tumor formation. Nonmelanoma tumors (e.g. lymphoma) were censored in this analysis. Shown P-values are for pairwise comparisons of the indicated background vs Tyr-RAS þ mice, and were computed with the log-rank test. Mice specifically lacking p19 ARF were generated by standard techniques with Cre-mediated excision of the neomycin marker embedded in exon 1b (NES and R DePinho, unpublished). Experimental cohorts were generated by initially crossing p16 (Chin et al., 1997) ), followed by heterozygous intercrosses. To minimize strain variability between these cohorts, best FVB males were selected using a markerassisted genotyping protocol to generate N2 backcrossed cohorts, and all animals analysed in this study were 475% FVB (N2). York, NY, USA) was used by standard methods on formalin-fixed, paraffin-embedded specimens. After secondary antibody treatment, the sections were stained using DAB solution followed by hematoxylin counter stain. All slides had one tissue section treated with PBS instead of primary antibody as a control p16
INK4a and p19 ARF in melanoma NE Sharpless et al types (Patel et al., 2000; Sharpless et al., 2001 Sharpless et al., , 2002 , epigenetic silencing of p16 INK4a through methylation was not detected in any p19 ARF À/À melanoma (not shown).
Similarly, p16
INK4a promoter methylation is uncommonly seen in human melanoma (Gonzalgo et al., 1997) . In total, 50% (nine of 18) p19 (Table 2) , were demonstrated in three tumors (e.g. # 13, 15 and 17, Figure 2c ). In contrast, p53 overexpression and/or point mutations were not detected in Tyr-RAS p19 ARF À/À tumors (Figure 2d) , consistent with an epistatic relationship between p19 ARF and p53 in this tumor type. Mdm2 overexpression was not detected in any of the tumors (not shown). In total, eight of 10 Tyr-RAS p16
INK4a À/À tumors demonstrated evidence of p53 pathway compromise. In accord with a previous study , our biochemical analyses from the two tumor cohorts suggest that most, if not all, ARF À/À melanomas showing absent or decreased expression in five of 11 tumors. Total protein lysates were prepared by briefly sonicating the tumor tissues in the presence of RIPA buffer with protease and phosphatase inhibitors, and analysed for p16 INK4a , p19 ARF and p53 as described (Sharpless et al., 2001 INK4a in a subset (e.g. #'s 5 and 9) of Tyr-RAS þ p19 ARF À/À tumors. p16 INK4a mutation status is indicated below the blots (PM, point mutation). The positive control for the IP is a p53À/À melanoma expressing wild-type p16
INK4a ), ND ¼ not determined. For cdk4 Western blots and immunoprecipitation, antibody C22 (Santa Cruz) was used. For immunoprecipitation analyses, 1 mg of protein extract was precleared by incubation with protein A-sepharose (Sigma) and preimmune serum, and incubated for 2 h with anti-cdk4 antibody. Extracts were incubated for 1 h after the addition of protein A-sepharose. Immunoprecipitated complexes were fractionated using SDS-PAGE and transferred to PVDF membrane. For the detection of point mutations, 2 mg of DNAse-treated RNA was used for cDNA synthesis (Superscript, Invitrogen). To determine the sequence of p53, cdk4 and p16
INK4a , primers spanning the entire open reading frames were used to amplify tumor cDNA. All mutations were confirmed by sequencing at least twice. Table 2 for further details) p16
INK4a and p19 ARF in melanoma NE Sharpless et al tumors from this model harbor concomitant inactivation of the Rb and p53 pathways.
This work builds upon previous results in the mouse Krimpenfort et al., 2001; Sotillo et al., 2001; Sharpless et al., 2002) to provide genetic evidence of a critical role of both products of the Ink4a/ Arf locus in the biology of melanoma. In contrast to previous studies, the evidence provided here benefits from the use of genetically similar mice followed over the same period in a common facility. As these strains differ only in their expression of p16
INK4a vs p19 
